StAbilize™

against antibody aggregation

Dr Chris Smith

Non-Executive Director

Chris is an Investment Manager at Brandon Capital Partners. Brandon Capital Partners makes seed and venture capital investments for the development and international growth of Australian life science companies. Before this Chris was a Business Development Manager with CSL Ltd, Australia’s largest pharmaceutical company and one of the top 10 biotechnology companies in the world. At CSL Chris was responsible for identifying and reviewing opportunities for CSL’s global R&D pipeline. As a consequence Chris has extensive experience with both in-licensing and out-licensing therapeutic drugs and R&D enabling platforms. Chris spent three years as a postdoctoral scientist at The University of Cambridge, UK. Chris has a PhD in Immunology conducted at the Walter and Eliza Hall Institute, and an MBA specialising in innovation and entrepreneurship from the University of Cambridge.

back to Management and Board